Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Current standard of care in BPDCN

In this video, Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses the current standard of care (SOC) in blastic plasmacytoid dendritic cell neoplasm (BPDCN), drawing focus on the use of tagraxofusp, as well as the use of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)-based regimens and the importance of transplantation. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Receiving grant support, paid to GWT-TUD, from Amgen, lecture fees, grant support, paid to the University of Leipzig, fees for serving on a steering committee, consulting fees, and travel support from Celgene, grant support, paid to GWT-TUD, from Janssen Biotech, grant support, paid to University Dresden, from Merck and Novartis, and lecture fees from Novartis